Press Releases

Press Releases

Date Title
February 25, 2020
UNITY Biotechnology Provides Pipeline and Business Updates
– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment – – Topline 12- and 24-week results now expected in 2H 2020 – – First patient dosed in phase 1b study to explore higher dose and repeat doses – – First-in-human study initiation for ophthalmology program expected in
February 24, 2020
UNITY Biotechnology, Inc. to Participate in the Cowen and Company 40th Annual Health Care Conference
SAN FRANCISCO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard , chairman and chief executive officer,
Displaying 11 - 12 of 12